- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04054037
A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)
August 11, 2019 updated by: Qin Ning
A Study of APASL ACLF Research Consortium (AARC) Standards on Diagnosis and Treatment of Patients With Hepatic B Virus Related Acute on Chronic Liver Failure (HBV-ACLF) in China (AARC China Study): a Multicentre Prospective Cohort Study
The AARC China Study is to establish a widely recognized and harmonized standard of patients with HBV-ACLF in the Asia Pacific region.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Acute on chronic liver failure (ACLF) is a clinically critical illness and has been extensively researched around the world.
However, there is a potential "communication barrier" in the ACLF study; that is, different countries and regions, or different research collaboration groups, follow different ACLF definitions and related standards, making researchers in this field confuse in understanding the research value of relevant research and interpreting the research results.
Important differences exist in the Asia-Pacific region and North America and Europe, such as the etiology, the clinical characteristics of the patient group, the requirements for cirrhosis, and the predisposing factors of the disease, making it necessary for China or the Asia-Pacific region to develop appropriate ACLF diagnosis standards and prognosis.
In recent years, Chinese experts have also focused on the research progress of APASL ACLF Research Consortium (AARC) in the Asia-Pacific region.
It is found that the AARC standards are more suitable for the diagnosis and treatment of patients with ACLF in China than the Western standards.
The ACLF prediction model (TPPM model) established by Professor Qin.N's team predicts that the prognostic efficacy of patients with HBV-ACLF is significantly better than that of Western prognosis.
The AARC China Study is to establish a widely recognized and harmonized standard of patients with HBV-ACLF in the Asia Pacific region.
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qin Ning, MD., PhD.
- Phone Number: 0086 2783662391
- Email: qning@vip.sina.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Qin Ning, Prof.
- Phone Number: 862883662391
- Email: qning@vip.sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with HBV-related acute-on-chronic liver failure
Description
Inclusion Criteria:
- Chronic liver disease: Chronic hepatitis B
Acute deterioration of liver function: more than one of the below criteria
- development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria)
- development of hepatic encephalopathy
- development of gastrointestinal hemorrhage
- development of jaundice (serum bilirubin greater than or equal to 3mg/dl)
- development of bacterial infection
- spontaneous bacteremia: positive blood cultures without a source of infection
- spontaneous bacterial peritonitis: ascitic fluid polymorphonuclear cells >250/µL
- lower respiratory tract infections: new pulmonary infiltrate in the presence of: i) at least one respiratory symptom (cough, sputum production, dyspnea, pleuritic pain) with ii) at least one finding on auscultation (rales or crepitation) or one sign of infection (core body temperature >38_C or less than 36_C, shivering, or leukocyte count >10,000/mm3 or <4,000/mm3) in the absence of antibiotics
- Clostridium difficile Infection: diarrhea with a positive C. difficile assay
- bacterial entero-colitis: diarrhea or dysentery with a positive stool culture for Salmonella, Shigella, Yersinia, Campylobacter, or pathogenic E. coli;
- soft-tissue/skin Infection: fever with cellulitis
- urinary tract infection (UTI): urine white blood cell >15/high-power field with either positive urine gram stain or culture;
- intra-abdominal infections: diverticulitis, appendicitis, cholangitis, etc.
- other infections not covered above;
- fungal infections as a separate category.
Exclusion Criteria:
- Patients who do not have chronic liver disease
- Patients who have hepatocellular carcinoma
- Patients who admitted for extrahepatic manifestations
- Patients who have HIV infection
- Patients who admitted for symptomatic control of chronic liver disease, other than acute deterioration of liver function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HBV-ACLF Group
Patients with HBV related acute on chronic liver failure
|
This is an observation study, no intervention will be indicated during diagnosis and treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-liver transplant mortality
Time Frame: 30 days, 90 days
|
Non-liver transplant mortality rate at 30 days, 90 days
|
30 days, 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression of Chronic liver disease
Time Frame: 3 years
|
Incidence of liver disease progression (such as cirrhosis, decompensation of liver function, liver cancer, liver transplantation, or liver related death)
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Qin Ning, MD., PhD., Department of infectious disease, Tongji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 2, 2019
Primary Completion (Anticipated)
April 1, 2022
Study Completion (Anticipated)
April 1, 2023
Study Registration Dates
First Submitted
April 13, 2019
First Submitted That Met QC Criteria
August 11, 2019
First Posted (Actual)
August 13, 2019
Study Record Updates
Last Update Posted (Actual)
August 13, 2019
Last Update Submitted That Met QC Criteria
August 11, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AARC China Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HBV
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Duke-NUS Medical School (Singapore)Not yet recruiting
-
Centre de Recherches et d'Etude sur la Pathologie...Completed
-
Aucta Pharmaceuticals, IncCompleted
-
The First Hospital of Jilin UniversityUnknown
-
Institute of Liver and Biliary Sciences, IndiaWithdrawn
-
Yi-Hua ZhouThe First People's Hospital of Kunshan; Taixing People's Hospital; Fourth People... and other collaboratorsCompleted
-
West China HospitalRecruitingKidney Transplantation | HBVChina
-
RenJi HospitalNot yet recruitingHBV | Liver Transplant Disorder
-
Fudan UniversityActive, not recruitingHBV | POST LIVER TRANSPLANTChina
-
Kaohsiung Medical University Chung-Ho Memorial...Recruiting
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of PittsburghCompletedChronic Low Back PainUnited States